The stock of Eagle Pharmaceuticals Inc (NASDAQ: EGRX) has increased by 13.29 when compared to last closing price of 4.59.Despite this, the company has seen a gain of 4.00% in its stock price over the last five trading days. GlobeNewsWire reported 2023-12-06 that — BARHEMSYS® (amisulpride) Injection is the first and only antiemetic approved by the U.S. Food and Drug Administration (“FDA”) for rescue treatment of postoperative nausea and vomiting (“PONV”) despite prophylaxis1 and is also approved for the treatment of PONV in patients who have not received prophylaxis and for the prevention of PONV — — In patients who experience PONV, the incidence of nausea is substantially greater than the incidence of vomiting2, 3 —
Is It Worth Investing in Eagle Pharmaceuticals Inc (NASDAQ: EGRX) Right Now?
Eagle Pharmaceuticals Inc (NASDAQ: EGRX) has a price-to-earnings ratio of 5.71x that is above its average ratio. Additionally, the 36-month beta value for EGRX is 0.43. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 1 rating it as “sell.”
The public float for EGRX is 11.43M and currently, short sellers hold a 10.58% ratio of that float. The average trading volume of EGRX on April 16, 2024 was 216.60K shares.
EGRX’s Market Performance
EGRX stock saw a decrease of 4.00% in the past week, with a monthly decline of -12.61% and a quarterly a decrease of 14.79%. The volatility ratio for the week is 8.70%, and the volatility levels for the last 30 days are 8.21% for Eagle Pharmaceuticals Inc (EGRX). The simple moving average for the past 20 days is 1.99% for EGRX’s stock, with a -52.63% simple moving average for the past 200 days.
Analysts’ Opinion of EGRX
Many brokerage firms have already submitted their reports for EGRX stocks, with Piper Sandler repeating the rating for EGRX by listing it as a “Underweight.” The predicted price for EGRX in the upcoming period, according to Piper Sandler is $17 based on the research report published on August 10, 2023 of the previous year 2023.
Piper Sandler, on the other hand, stated in their research note that they expect to see EGRX reach a price target of $17, previously predicting the price at $26. The rating they have provided for EGRX stocks is “Underweight” according to the report published on August 09th, 2023.
RBC Capital Mkts gave a rating of “Outperform” to EGRX, setting the target price at $52 in the report published on April 07th of the previous year.
EGRX Trading at -6.87% from the 50-Day Moving Average
After a stumble in the market that brought EGRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -83.44% of loss for the given period.
Volatility was left at 8.21%, however, over the last 30 days, the volatility rate increased by 8.70%, as shares sank -14.05% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -14.47% lower at present.
During the last 5 trading sessions, EGRX rose by +4.00%, which changed the moving average for the period of 200-days by -73.42% in comparison to the 20-day moving average, which settled at $5.06. In addition, Eagle Pharmaceuticals Inc saw -0.57% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at EGRX starting from Tarriff Scott, who sale 10,694 shares at the price of $13.87 back on Nov 02 ’23. After this action, Tarriff Scott now owns 545,447 shares of Eagle Pharmaceuticals Inc, valued at $148,326 using the latest closing price.
Tarriff Scott, the CEO of Eagle Pharmaceuticals Inc, sale 10,925 shares at $13.82 during a trade that took place back on Nov 01 ’23, which means that Tarriff Scott is holding 556,141 shares at $150,984 based on the most recent closing price.
Stock Fundamentals for EGRX
Current profitability levels for the company are sitting at:
- 0.14 for the present operating margin
- 0.72 for the gross margin
The net margin for Eagle Pharmaceuticals Inc stands at 0.1. The total capital return value is set at 0.08. Equity return is now at value 4.88, with 3.04 for asset returns.
Based on Eagle Pharmaceuticals Inc (EGRX), the company’s capital structure generated 0.22 points at debt to capital in total, while cash flow to debt ratio is standing at 0.06. The debt to equity ratio resting at 0.28. The interest coverage ratio of the stock is 5.25.
Currently, EBITDA for the company is 65.48 million with net debt to EBITDA at 1.45. When we switch over and look at the enterprise to sales, we see a ratio of 0.64. The receivables turnover for the company is 1.66for trailing twelve months and the total asset turnover is 0.47. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.16.
Conclusion
In conclusion, Eagle Pharmaceuticals Inc (EGRX) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
